Isoflavone

Osteoporosis An acceleration of bone loss occurs after the menopause, increasing the risk of osteoporosis. The usual treatment for osteoporosis includes hormone therapy. It has been observed that there is a lower incidence of osteoporosis and hip fractures in south east Asian countries where there is a greater dietary intake of phytoestrogens and it has been suggested that phytoestrogens such as genistein may provide protection from bone loss, as demonstrated in the rat model. Rat model studies have shown less bone loss with soya protein supplementation; 0.5 mg day genistein inhibited bone loss, but 1.6 mg genistein day showed no effect6. Genistein may act as an inhibitor of osteoclasts, which break down and absorb bone. Although positive skeletal effects of isoflavones have been demonstrated from studies in rats, there have been no peer reviewed published clinical trials of the effects of natural isoflavones on bone mass changes in humans. Published papers from such trials, on the effects of isoflavones on bone density, are anticipated in the next few years. Ipriflavone, a synthetic isoflavone derivative, has been studied extensively with regards to the prevention of osteoporosis. It appears to inhibit bone resorption i.e. helps slow bone loss, so improving bone density ipriflavone is, however, devoid of oestrogenic activity ; . These positive findings cannot be directly extrapolated to natural isoflavones found in the diet, but they should be the basis for further research, especially as daidzein one of the two principal soya isoflavones ; is one of the main metabolites of ipriflavone. Hence at present there is only tentative evidence to indicate that naturally occurring phytoestrogens have similar effects in maintaining bone density to those of the related ipriflavone, although emerging evidence suggests these substances are biologically active in experimental models. d ; Coronary Heart Disease The mortality from coronary heart disease CHD ; varies a great deal between countries. In the USA, 300 per 100, 000 men, aged 40 - 69 years, die from CHD each year. The corresponding figure in Japan is 50 per 100, 0002. The higher content of phytoestrogens in the Japanese diet has been highlighted as a potential reason for this difference. Soya has been shown to have a plasma cholesterol lowering LDL cholesterol ; effect, as effective as HRT agents. 47g soya protein day has been shown to reduce LDL cholesterol by 12.9%2. However, it must be appreciated that isolated isoflavones without soya protein have no effect on cholesterol, but they do appear to improve arterial compliance. Soya protein without isoflavones does not have a cholesterol lowering effect. Therefore the beneficial, potentially cardioprotective effect appears to be due to synergism of the components in soya, although further research is required to understand the exact mechanism of cholesterol lowering by soya proteins. The proposed mechanisms of actions involve isoflavones acting as oestrogens and exerting an antioxidant action. The protective effect of linseed may be partly due to its a- linolenic acid content.
The prescribing physician should avoid prescribing this medication to women who are pregnant, nursing, or have a likelihood of becoming pregnant and isoniazid. Multigenerational Animal Studies of Soy Protein Isolate: Is There Evidence for Adverse Developmental Effects? Thomas M. Badger, Martin Ronis and Reza Hakkak. Arkansas Children's Nutrition Center and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR. Three primary proteins are used in infant formulas sold in the United States: soy protein isolate SPI ; , bovine casein CAS ; protein and bovine whey WPH ; protein. Formula made with SPI contains high concentrations of many substances not normally found in human breast milk, which has led to concerns over possible adverse health effects in infants consuming formula compared with human milk. Phytochemicals similar to those found in soy infant formula have been reported to cause deleterious effects, such as infertility, thyroid disorders, central nervous system disorders and even death. There is a paucity of data on developmental, physiological, neurophysiological, behavioral, metabolic and molecular effects of soy diets during pregnancy and infancy. We have studied the effects of SPI in short-term, long-term and multigenerational studies in rats because of obvious ethical and safety concerns about studies in infants. Aside from minor differences in body weight gain profiles, SPI-fed rats did not differ from CAS-fed rats in development, organ weights, in vitro hepatic metabolism or reproductive performance. However, puberty in females rats fed SPI diets was accelerated P 0.05 ; compared with those fed CAS P 0.05 ; . Although male rats fed SPI diets had normal serum testosterone levels, female rats fed SPI had altered serum estrogen profiles compared with rats fed CAS P 0.05 ; . Female rats fed SPI or treated with genistein had reduced incidence of chemically induced mammary and 0.05 ; compared with CAS controls. Recolon cancers P sults from our animal studies and from clinical studies of infants and adults consuming SPI suggest that subtle effects can occur. Determining the long-term health consequence implications of early diet exposure to SPI still awaits further research, but epidemiological and laboratory data suggest potential benefits to soy infant formula rather than adverse effects. Supported by Arkansas Children's Nutrition Center, a U. S. Department of Agriculture, Agricultural Research Service Program. ; Effects of Developmental Exposure to Genistein, a Soy Phytoestrogen, in an Experimental Animal Model. Retha Newbold. Developmental Endocrinology Section, Laboratory of Molecular Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC. Genistein, a naturally occurring isoflavone, interacts with estrogen receptors and multiple molecular targets. Human exposure to genistein is predominantly through dietary consumption of soy products, but its use as a nutritional supplement and pharmaceutical has dramatically increased in the past few years. This increase is primarily a result of reports suggesting that phytoestrogens, particularly genistein, may lower the risk of severe chronic diseases and protect against various cancers. Although much attention has been given to the beneficial effects of dietary estrogens, it is important to balance these against the potential for deleterious effects, especially if exposures occur during critical early stages of human development. It is well known that the developing fetus is uniquely sensitive to perturbation with estrogenic chemicals; the carcinogenic effect of prenatal exposure to diethylstilbestrol DES ; is a classic example. Because infants and children are exposed to genistein in soy-based infant formulas and soy products mar.
In summary, adm cannot show a long and safe history of use because there is no evidence to substantiate their claim that isoflavones have been consumed by millions of humans for over two thousand years and vasodilan.

Bioaccumulation of xenoestrogens in breast and other fatty tissues from lifelong exposure to plastics, pesticides, solvents and other environmental chemicals. If you are post-menopausal, carry 10 + pounds extra weight, eat commercially produced meat and dairy products, live in an agricultural area pesticide exposure ; , have average exposure to solvents, plastics, and other xenoestrogens, it is reasonable to assume your total estrogen environment is high and phytoestrogens would likely be protective for you. Interestingly, post-menopausal women with breast cancer have lower plasma levels of soy isoflavones genistein and diadzein than are found in healthy controls [Murkies et al., 2000]. On the other hand, if you are an underweight, vegan no meat or dairy consumption ; post-menopausal woman who has taken precautions in life to avoid xenoestrogen exposure no guarantee ; , you may have low estrogen levels after menopause, and it might be prudent for you to avoid soy consumption. Brief Exposure Time Some studies have shown that with short duration exposure say, 1-2 weeks ; , soy can produce an estrogenic effect such as increasing breast tissue density [McMichaelPhillips et al., 1998]. One study looked at the effects of soy consumption on breast markers in premenopausal women eating 60 grams soy 45mg isoflavones ; over a short 2-week period. The results suggested a weak estrogenic reponse on breast tissue though there was no cell proliferation effect detected ; [Hargreaves et al., 1999]. However, studies that have re-examined the effect with continued dosing show ablation of this short-term effect. Recently conducted yearlong studies indicate that isoflavone supplements do not affect breast tissue density in premenopausal women, and may decrease density in post-menopausal women [Messina & Loprinzi 2001]. In contrast, hormone replacement therapy increases breast density and increases risk of breast cancer. ; In addition, an in vitro study that demonstrated a growth promoting effect for soy during brief exposure showed that, with prolonged exposure, genistein resulted in a decrease response of estrogen receptors to stimulation by estradiol [Wang et al., 1996]. Late Exposure Time It appears that the strongest cancer preventing effects of soy may be achieved when exposure is timed during puberty or earlier ; [Aldercreutz et al., 2002; Lamartiniere et al., 1998, 1995; Barnes 1997]. Animals exposed to genistein prior to or during puberty experience a longer latency period before developing carcinogen-induced mammary tumors and have fewer tumors [Jin & MacDonald 2002; Murrill et al., 1996; Barnes 1997]. Studies of Asian women suggest that those who consume a traditional diet high in soy products have a low incidence of breast cancer, but that among emigrants to the U.S. the second generation--but not the first--loses this protection, suggesting early exposure to soybean foods protects against later development of breast cancer [Lamartiniere 2000]. Early exposure to soy isoflavones promotes maturity differentiation ; of breast tissue, and appears to alter the endocrine system in ways that reduce breast cell proliferation in vivo [Lamartiniere et al., 1995]. While this finding is of little relevance for your current situation, it does suggest that your pre-pubertal and adolescent female relatives who are increased risk for breast cancer due to family history of the disease ; should consider adding soy products to their diet! Inactive Compound Tested Bowel Conversion When humans eat soy foods, our digestive process alters the phytoestrogens they contain. Tion of the isoflavones in modest amounts of soy products can result in circulating concentrations of phytoestrogens that exceed the amounts of endogenous estrogens 1, 2 ; . The use of soy has significantly increased in recent years, as has the use of soy extracts as dietary supplements. In view of the lack of regulation of such extracts by the FDA, more studies are needed to ascertain both the positive and negative health effects of ingestion of isoflavones. Considerable attention has been focused on phytoestrogens as being a potential benefit in the prevention of atherosclerosis or as anticancer agents 3, 4 ; . Considerable literature also exists regarding the anti-inflammatory activities of the isoflavones. Isoflavones inhibit adhesion molecule expression 58 ; , alter arachidonic acid metabolism 9 ; , inhibit oxygen radical generation 10, 11 ; , and inhibit chemotactic factor production 12 ; . Nutrient intake can also influence cytokine production and reactive oxygen species, thus influencing antioxidant defense and the inflammatory process 13 ; . Genistein, a principal soy isoflavone, is a tyrosine and ketorolac. External genital and perianal warts are cause by a virus called human papilloma. Mgi pharma markets its products through direct sales force within the united states and through alliances with other pharmaceutical or biotechnology companies in other countries and ketotifen. Recently, the environment of medical economics has become harder. In the field of medical insurance systems, the implementation of comprehensive medicare has spread, resulting in National Health Insurance NHI ; points for clinical laboratory tests being calculated on a lump-sum payment basis. The DRG-PPS diagnosis related group prospective payment system ; is one of the measures of comprehensive medicare, and its probable introduction this fiscal year to inpatients of advanced treatment hospitals, such as university hospitals is indicated. Should this system be determined to apply to outpatients in the future is expected to have a considerable impact on what clinical laboratory tests should be performed, and physicians will be obliged to adequately deal with it. In dealing with the DRG PPS, the first thing to be done is to secure high-quality clinical laboratory tests for patients. For this purpose, it is necessary to understand and practice the proper uses of tests, and for this, it is critical to prepare a guideline for the proper uses of tests conforming to the DRG PPS. Presently, the Japanese Society of Laboratory Medicine JSLM ; is preparing the guideline for the effi.
And short follow-up period cannot establish safety for use in such patients. Two more recent studies examined the efficacy of soy protein to treat hot flash symptoms. Albertazzi et al82 compared soy protein, 60 g d 76 mg of isoflavones ; , to placebo in 104 women during a 12-week period in a double-blind, randomized fashion and reported a moderate but statistically significant decrease in hot flashes. By week 12, patients treated with soy protein had a 45% reduction in hot flash frequency compared with a 30% reduction in the placebo arm P .01 ; . Gastrointestinal adverse effects were equal in both groups. Finally, a recent trial randomized 123 women to isoflavone, 90 mg d, or placebo and found no significant difference between the 2 groups with respect to reduction of hot flash symptoms.83 In summary, the evidence to date is mixed but suggests that soy protein and isolated isoflavones do not reduce hot flashes substantially.84 The long-term safety of soy protein in patients with a previous history of breast or uterine cancer remains to be established. Nonhormonal Treatments Newer Antidepressants.--Newer antidepressant agents have become the most promising class of medications for nonhormonal treatment of hot flashes. These agents affect the release and reuptake of a variety of neurotransmitters at multiple sites in the central nervous system, including the hypothalamus. Although their effect on serotonin and norepinephrine reuptake are these agents' best defined mechanisms of action, other specific and nonspecific effects on neurotransmitter kinetics may contribute to their clinical effects. During the 1990s, some clinicians anecdotally observed a decrease in hot flashes in postmenopausal women being treated for depression with selective serotonin reuptake inhibitors SSRIs ; or other newer antidepressants. Based on these observations, studies were undertaken to examine the role of these agents for treating hot flashes. The first antidepressant agent to undergo clinical investigation was venlafaxine.85 Venlafaxine is a novel antidepressant that inhibits both serotonin and norepinephrine reuptake. The agent is thought primarily to inhibit serotonin reuptake at lower doses and to inhibit norepinephrine reuptake more profoundly at higher doses. Mayo Clinic investigators performed a nonrandomized series of open-label venlafaxine 25 mg d ; use in 28 breast cancer survivors and found a 50% reduction in the combined end point of hot flash frequency and severity.85 A similar response was found in 16 men undergoing androgen ablation for the treatment of prostate cancer.86 Based on these results, investigators performed a double-blind, placebo-controlled trial in which 191 patients were randomized to placebo or 1 of and lamictal. SAM-e 200mg 20 Tablets by Natrol SAM-e 200mg 90 Tablets by Nature Made SAW PALMETTO 160mg 240 Softgels by BIOVEA SELENIUM 100mcg 120 Capsules by BIOVEA SEROTAIN 100mg 60 Capsules by Natrol SERRAPEPTASE 40, 000 IU 90 Capsules SLIMMING PATCH by Curb Your Cravings SOMESTA 30 Capsules by Newton-Everett Biotech SOY ISOFLAVONES 50mg 120 Softgels by TruNature SOY ISOFLAVONES 500mg 60 Capsules by BIOVEA SPIRULINA 500mg 100 Tablets by BIOVEA ST. JOHN'S WORT 450mg 240 Capsules by BIOVEA STACKER 2 100 Capsules by NVE Pharmaceuticals.

If they came out and said categorically that isoflavones for postmenopausal women would reduce the risk of heart disease, then i would take a tablet every day and lamotrigine.
2.2.3. In vitro skin permeation studies The skin was prepared as described prveviously [5]. In vitro skin permeation studies were performed using a Keshary-Chien diffusion cell. The amount of drug permeated was determined by removing 1 mL samples at appropriate time intervals up to 24 and were immediately analyzed for the drug concentration by a UV spectrophotometry Secomam, Anthelie, France ; at the ?max value of 226 nm. The volume was replenished with an equal quantity of pre-warmed receiver solution. Skin irritation test were performed on mice using marketed adhesive tape as control [6]. 3. Results and Discussion Monolithic matrix type TTS loaded with ATL were prepared by solution casting method. Totally seven formulations were prepared by varying three parameters viz., grafting ratio, drug loading and penetration enhancers. PEG-6000 is used in concentrations of 20 % w plasticizer; polymeric films with concentrations less than 20 % w w plasticizer were somewhat brittle and lacked the folding endurance. However, the films with a plasticizer concentration over 30 % w w did not further improve the film properties compared to those prepared with 20 % w w ; The films formed were slightly opaque and had uniform thicknesses varying from 0.082 to 0.112 mm. Drug content of the films varied from 94.26 to 98.17 %. The process employed to prepare films in this study was capable of producing films with a uniform drug content and a minimum batch variability. Weight of the completely dried film was recorded in the range of 1.13 to 2.39 mg. Folding endurance was varied from 21 to 32; formulations F1P3 and F3P2 exhibited maximum and minimum folding endurances, respectively. FT-IR spectra of the pristine ATL and the drug-loaded film showed characteristic bands due to different functional groups have also appeared in the ATLloaded films, indicating the chemical stability of ATL in the chosen polymeric matrix. This also indicates that ATL is not involved in any chemical reactions with either the polymer or the excipients used. DSC scans of the pristine drug, placebo film and the drug-loaded film were taken. Endothermic peaks of ATL appeared at its melting point, 158 oC, which appears at 152C in the DSC plots of the ATL-loaded film with a much lesser intensity. A slight shifting of the peak indicates no recrystallization of the pristine drug within the polymer matrix due to molecular interactions between the drug and the polymer. This further confirms a uniform dispersion of ATL in the polymer matrix. The X -ray diffraction patterns of pristine drug, drug-loaded film and placebo film confirms that a portion of the drug is molecularly dispersed in the polymer matrix film. Scanning electron microscopy of placebo films exhibited a clear and homogenous surface, whereas drug-loaded films showed a uniform distribution of ATL in the polymeric matrix Fig. 1 ; . 3.1. Skin permeation studies In vitro skin permeation of xanthan films was studied at 37 oC using the freshly excised hairless rat skin, Skin permeation profiles of the formulations containing graft copolymer at various grafting ratios are shown in Fig. 1. The total amount of drug permeated from these formulations was about 85 % at the end of 24 h. was observed that the cumulative drug permeated through the rat skin was not very different. However, the enhanced skin permeation of the drug is due to its faster release rate from the transdermal film and due to less partitioning of the drug with the polymer. The skin permeation studies at various drug loadings 20 %, 30% and 40% ; have been studied and these results are depicted in Fig. 1, which suggest that as the concentration of drug increased, the rate of permeation also increased. This type of increased rate and extent of permeation may be due to an increase in the rate of diffusion at the higher concentrations of the drug. Permeation profiles of the formulations containing penetration enhancers are shown in Fig. 2. About 87 % of the drug is permeated fo r, for example, isoflavones breast.